Neurodegenerative Disease Market By Drug Class (Dopamine inhibitors, NMDA, Others), By Indication (Huntington disease, Alzheimer’s disease, Others) Regional Analysis & Forecast - 2026

The neurodegenerative disease, also known as neurodegeneration is a condition in which there are damage or wear and tear of the nerve cells. The patient with the neurodegenerative disease does not have the ability to make decisions, and that will later result in the memory loss. The diseases coming under the category of the neurodegenerative diseases are Huntington disease, Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis. Neurodegenerative diseases are specified by neuronal death in the brain and/or central nervous system (CNS), which lead to a progressive decline in functional neurological capabilities. It has a devastating effect on quality of life and independence, often requiring full-time care during the later disease stages.

Market Overview

The global neurodegenerative disease market accounted for USD XX billion in 2018 and is expected to reach XX billion USD by 2026, growing at a CAGR of XX% during the forecast period. The market for the neurodegenerative disease is having a robust growth due to the continuous developments that are made in the medical sector including both in the treatment and the diagnosis of neurological disorders. The other factor that contributes to the growth of the market is the growth in the geriatric population, which is more prone to neurological diseases. In the developing region segments, the physicians are more familiar with the neurological diseases and its treatment methods hence triggering to the growth of the market.

Alzheimer’s disease is one of the sixth leading causes of death in the US and is more prevalent among people above 65 years age. The number is going to increase during the forecast period and is worsening the situation in the coming years. This rise in prevalence of neurodegenerative disorders contributes to the growth of the market. The strong pipeline of products for neurodegenerative diseases and new drug launches are the other driving factors. In the Alzheimer’s market, drugs like anti-amyloid protein agents, GABA receptor modulators, and nicotinic and cholinergic receptor agonists are anticipated to influence the market growth however in the Parkinson’s disease market will be driven due to launch of drugs like dopamine receptor agonists and reuptake inhibitors, glutamate receptor modulators, and adrenergic and adenosine antagonists.

The global neurodegenerative market is facing multiple patent expiries that are likely to restrain the market. Some of the patents like Stalevo 50 patent expiring in June 2020, Comtan’s patent expiring in 2019, and Azilect’s in May 2017. Hence, it is expected that the market will face a downfall in the coming years. Further, the drug Rilutek used to treat Amyotrophic Lateral Sclerosis will lose its patent protection in 2018, thus reducing the market growth. These continuous patent expiries will enable generics and players in offering low priced products from entering the market and causing a loss in the revenues of major key players, which is expected to impede the growth of the market. The other factors restraining the market include disease complexity and stringent regulations, the absence of the developed curative treatment, and the lack of awareness among the people in the under-developed regions. The medications that are currently available for such diseases and disorders are gaining success only in providing symptomatic relief. The market, hence, has a high potential for growth and should be tapped at the earliest.

Key Developments

• In Feb 2019, Orion announces an intention to submit NDA of Levosimendan to the US FDA for amyotrophic lateral sclerosis.


• In Dec 2018, BrainStorm Cell Therapeutics announced the U.S. Food and Drug Administration (FDA) acceptance of the Investigational New Drug (IND) application for initiating a Phase 2 clinical trial of NurOwn to treat progressive multiple sclerosis (MS).

Segmentation

The global neurodegenerative disease market is segmented into its drug class, indications and the region.

Based on the Drug class: Dopamine inhibitors, NMDA, and SSRIs.

Based on Indications: Huntington disease, Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis. Out of these, Alzheimer’s disease is the most prevalent, followed by Parkinson’s disease.

Based on the Region: The Asia Pacific, the Middle East, and Africa, Latin America, North America, Western European, and Eastern Europe. The Asia Pacific region is contributing to the maximum share in the neurodegenerative disease market due to the existence of a large population base and the increase in cases of neurodegenerative disorders. North America and the European regions will experience significant growth in the market in the coming years owing to the increasing cases of neurological disorders.

The key market players that are involved in the global neurodegenerative disease market include Novartis International AG, Pfizer Inc., Merck Serono, Biogen Idec, Teva Pharmaceutical Industries Ltd, UCB, Bayer Schering, Boehringer Ingelheim GmbH, Sanofi S.A., and GlaxoSmithKline Plc. among others.